Accessibility Menu
Lakefront Biotherapeutics logo

Lakefront Biotherapeutics(OTC) GLPGF

Market Cap$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)+165%
5 Year-56%
1 Year-8%
1 Month-7%
$26.24
+0.00%
+0.00Today
Lakefront Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 26.242026-08-06
Lakefront Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.55%USD 28.082026-05-04
1 month-6.55%USD 28.082026-05-04
3 month-6.55%USD 28.082026-05-04
Year to date-16.14%USD 31.292025-12-01
1 year-8.35%USD 28.632025-07-29
3 year-37.15%USD 41.752023-07-26
5 year-56.11%USD 59.792021-08-04
Since inception+165.05%USD 9.902005-11-30

Lakefront Biotherapeutics Financials at a Glance

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€990.25M

Net Income (TTM)

€596.39M

EPS (TTM)

$10.52

P/E Ratio

2.49

Dividend

$0.00

Beta (Volatility)

-0.02 (Low)

Price

$26.24

Volume

48

Open

$26.24

Previous Close

$26.24

Daily Range

$26.24 - $26.24

52-Week Range

$26.24 - $34.00

Estimated Earnings Date

Feb 23, 2026

GLPGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakefront Biotherapeutics

Lakefront Biotherapeutics is a fully-integrated biopharmaceutical company focused on developing innovative therapies for unmet medical needs. The company has a diverse pipeline of investigational drugs targeting various inflammatory and autoimmune disorders, showcasing its commitment to advancing healthcare solutions.

Products and Services
  • Filgotinib: A JAK1 inhibitor in clinical trials for multiple inflammatory disorders
  • GLPG1972: Successfully completed Phase 2b trial for osteoarthritis
  • Toledo Molecules: Targeting inflammatory conditions with several candidates in development
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Strategic collaborations with major pharmaceutical companies enhance market reach
  • Focus on addressing significant unmet medical needs drives potential revenue growth
Financial Highlights
  • Recent quarterly revenue of €12.1 million, showing a positive trend
  • Trailing twelve months (TTM) net profit margin of 46.83% indicates strong profitability
  • Current ratio of 30.48 suggests excellent liquidity position
Lakefront Biotherapeutics operates in the biotechnology sector, emphasizing the development of therapies for conditions with limited treatment options. The company’s flagship product, Filgotinib, is undergoing extensive clinical evaluation, which could significantly impact its market position. The successful completion of the Phase 2b trial for GLPG1972 further solidifies the company’s potential in the osteoarthritis market. Strategic partnerships with industry leaders like Gilead Sciences and AbbVie enhance Lakefront's capabilities and market access, positioning it favorably for future growth. The financial metrics reflect a robust operational framework, with a strong liquidity position and impressive profit margins, indicating effective management and operational efficiency. Overall, Lakefront Biotherapeutics presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapeutic solutions.
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

196

CEO

Henry O. Gosebruch, CPA

Website

www.galapagos.com

Headquarters

Mechelen, BU 2800, BE

GLPGF Financials

Key Financial Metrics (TTM)

Gross Margin

98.01%

Operating Margin

36.43%

Net Income Margin

46.83%

Return on Equity

16.88%

Return on Capital

14.48%

Return on Assets

14.49%

Earnings Yield

40.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.66M

Volume

48

Avg. Volume

0.75

Financials (TTM)

Gross Profit

€965.05M

Operating Income

€391.76M

EBITDA

€448.65M

Operating Cash Flow

-€169.59M

Capital Expenditure

-€4.61M

Free Cash Flow

-€174.19M

Cash & ST Invst.

€2.24B

Total Debt

€6.35M

Lakefront Biotherapeutics Performance Analysis

Lakefront Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 253,546,503-55.8%
20232023-12-31EUR 259,169,3572.2%
20242024-12-31EUR 298,166,97515.0%
20252025-12-31EUR 1,255,258,568321.0%
Lakefront Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.0%
Q42025-12-311165.4%
Q12026-03-31-99.3%
Q22026-06-3086.0%
Lakefront Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -3.4954.1%
20232023-12-31EUR 3.47N/A
20242024-12-31EUR 1.22-65.0%
20252025-12-31EUR 5.50351.9%
Lakefront Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-92.5%
Q42025-12-31482.6%
Q12026-03-31-98.2%
Q22026-06-30-85.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€12.10M

-81.5%

Gross Profit

€3.01M

-95.0%

Gross Margin

24.90%

N/A

Market Cap

$1.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.81M

N/A

Employees

452

N/A

Net Income

€2.10M

+102.0%

EBITDA

-€44.95M

+55.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€2.24B

-27.7%

Total Debt

€6.35M

-24.8%

Accounts Receivable

€56.21M

-36.0%

Inventory

€0.00

-100.0%

Long Term Debt

€4.77M

-21.2%

Short Term Debt

€3.18M

+32.7%

Return on Assets

14.49%

N/A

Return on Invested Capital

11.62%

N/A

Free Cash Flow

€14.28M

+112.6%

Operating Cash Flow

€14.31M

+113.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHWGYShandong Weigao Group Medical Polymer Company Limited
$1.50+0.00%
ONTTFOxford Nanopore Technologies plc
$2.40+12.68%
BVNKFBavarian Nordic A/S
$32.57+0.00%
BVNRYBavarian Nordic A/S
$11.34-0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About GLPGF

What is the current price of Lakefront Biotherapeutics?

Lakefront Biotherapeutics is trading at $26.24 per share.

What is the 52-week range for Lakefront Biotherapeutics?

Over the past 52 weeks, Lakefront Biotherapeutics has traded between $26.24 and $34.00.

How much debt does Lakefront Biotherapeutics have?

As of the most recent reporting period, Lakefront Biotherapeutics reported total debt of €7.27M.

How much cash does Lakefront Biotherapeutics have on hand?

Lakefront Biotherapeutics reported €155.43M in cash and cash equivalents in its most recent financial results.

What is Lakefront Biotherapeutics’s dividend yield?

Lakefront Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services